

Curriculum Vitae

Seung Kew Yoon, MD, PhD

Education and Training

- 1979 – 1985, M.D. College of Medicine, The Catholic University Medical College, Korea
- 1986 – 1989, Residency in Internal Medicine, Catholic Medical Center,
The Catholic University of Korea
- 1987 – 1992 M.S. The Catholic University Graduate School
- 1992 – 1995 Ph.D. The Catholic University Graduate School

Professional Experience

- 2005.3-present, Professor, Division of Hepato-Gastroenterology, Dept. of Internal
Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea
- 2004 – present, Director of WHO Collaborating Center of Viral Hepatitis in Korea
The Catholic University of Korea

Publications

1. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. *J ImmunoTher Cancer* 2020;8:e000301.
2. SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells. *Anticancer Res* 2020;40(4):2033-2042.
3. Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms. *Clin Mol Hepatol* 2020;26(1):78-82
4. Association of prophylactic anti-HBV therapy with improved long-term survival in patients with hepatocellular carcinoma undergoing transarterial therapy. *Clin Infect Dis* 2019;ciz860
5. High tolerance of hepatitis B virus to thermal disinfection. *J Hepatol* 2019;71(6):1249-1251
6. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. *J Hepatol* 2019;71(2):289-300.
7. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. *Gastroenterology* 2019;157(1):227-241
8. Serine Protease HtrA2/Omi Deficiency Impairs Mitochondrial Homeostasis and Promotes Hepatic Fibrogenesis via Activation of Hepatic Stellate Cells. *Cells* 2019;8(10):1119

9. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: A large-scale, propensity score analysis. *Gut* 2020;69(7):1301-1308
10. Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naive Patients with Chronic Hepatitis B in Korea. *Dig Dis Sci* 2019;64(7):2039-2048
11. Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma: role of salvage surgery. *Hepatobiliary Surg Nutr* 2019;8(5):569-571
12. Impact of Enterococcal Bacteremia in Liver Transplant Recipients. *Transplant Proc* 2019;51(8):2766-2770
13. Invasive fungal infection in liver transplant recipients in a prophylactic era A multicenter retrospective cohort study in Korea. *Medicine (Baltimore)* 2019;98(26):e16179
14. Solitary fibrous tumor of the liver mimicking malignancy. *Korean J Intern Med* 2020;35(3):734-735
15. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response. *HPB (Oxford)* 2019;21(12):1718-1726
16. Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma. *Anticancer Res* 2019;39(7):3909-3916
17. Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression. *Sci Rep* 2019;9(1):9137
18. Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8(+) T Cells in Patients Considered Immune Tolerant. *Front Immunol* 2019;10:1319
19. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. *Dig Dis Sci* 2019;64(10):2992-3000
20. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. *J Med Virol* 2019;91(6):1104-1111
21. Liver-specific Gene Delivery Using Engineered Virus-Like Particles of Hepatitis E Virus. *Sci Rep* 2019;9(1):1616
22. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol* 2019;17(9):1850-1859.e4
23. Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma. *Int J Clin Oncol* 2019;24(6):666-676
24. A Fierce Battle in the Liver to Kill the Enemy From Gut. *Gastroenterology* 2019;156(6):e4-e6

25. Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them. *Clin Mol Hepatol* 2018;24(4):374-383
26. Clinical outcome of 1,000 consecutive cases of liver transplantation: a single center experience. *Ann Surg Treat Res* 2018;95(5):267-277
27. Carbapenem-resistant *Acinetobacter baumannii* Bacteremia in Liver Transplant Recipients. *Transplant Proc* 2018;50(4):1132-1135
28. Impact of Pretransplant Infections on Clinical Course in Liver Transplant Recipients. *Transplant Proc* 2018;50(4):1153-1156
29. Elk-3 Contributes to the Progression of Liver Fibrosis by Regulating the Epithelial-Mesenchymal Transition. *Gut Liver*. 2017;11(1):102-111
30. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients. *J Viral Hepat* 2018;25(10):1189-1196
31. Diagnosis of Liver Fibrosis With *Wisteria floribunda* Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients. *Ann Lab Med* 2018;38(4):348-354
32. Molecular Pathogenesis of Radiation-Induced Cell Toxicity in Stem Cells. *Int J Mol Sci* 2017;18(12):2749
33. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. *Aliment Pharmacol Ther* 2018;47(6):816-825
34. Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling. *Clin Mol Hepatol* 2018 Sep;24(3):302-310
35. Outcome of donor biliary complications following living donor liver transplantation. *Korean J Intern Med* 2018 ;33(4):705-715
36. Serial Monitoring of Immune Markers Being Represented Regulatory T Cell/T Helper 17 Cell Ratio: Indicating Tolerance for Tapering Immunosuppression after Liver Transplantation. *Front Immunol* 2018;9:352
37. A simplified prognostic model to predict mortality in patients with acute variceal bleeding. *Dig Liver Dis* 2018 ;50(3):247-253
38. ¹⁸F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. *Eur J Nucl Med Mol Imaging* 2018;45(3):384-391
39. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. *Clin Mol Hepatol* 2017;23(2):128-137
40. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy. *Gut Liver* 2017;11(6):870-877

41. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. *J Vasc Interv Radiol* 2017 ;28(11):1503-1511.e2
42. -Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. *Ther Adv Med Oncol* 2017;9(10):615-626
43. CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner. *Sci Rep* 2017;7(1):6387
44. IFN-lambda 4 potently blocks IFN-alpha signalling by ISG15 and USP18 in hepatitis C virus infection. *Sci Rep* 2017;7(1):3821
45. The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation. *Liver Transpl* 2017;23(8):1023-1031
46. Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133. *Sci Rep* 2017;7:45557
47. GRIM-19 Restricts HCV Replication by Attenuating Intracellular Lipid Accumulation. *Front Microbiol* 2017;8:576
48. Long-term outcome of liver resection versus transplantation for hepatocellular carcinoma in a region where living donation is a main source. *Ann Transplant* 2017;22:276-284
49. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1 α . *Oncol Rep* 2017;37(2):813-822
50. Aronia melanocarpa Extract Ameliorates Hepatic Lipid Metabolism through PPAR γ 2 Downregulation. *PLoS One* 2017;12(1):e0169685
51. Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea. *PLoS One* 2017;12(1):e0170362
52. Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma. *Cancer Chemother Pharmacol* 2017;79(1):81-88
53. Hemorheological alteration in patients clinically diagnosed with chronic liver diseases. *J Korean Med Sci* 2016;31(12):1943-1948
54. RAR-Related Orphan Receptor Gamma (ROR- γ) Mediates Epithelial-Mesenchymal Transition Of Hepatocytes During Hepatic Fibrosis. *J Cell Biochem* 2017;118(8):2026-2036
55. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. *J Cell Biochem* 2017;118(8):2026-2036
56. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. *Cancer Res Treat* 2016;48(4):1243-1252

57. ASXL2 promotes proliferation of breast cancer cells by linking ER alpha to histone methylation. *Oncogene* 2016;35(28):3742-52
58. On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients. *Eur J Gastroenterol Hepatol* 2016;28(10):1179-87
59. Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. *Hepatol Res* 2016;46(7):657-68
60. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. *Radiology* 2016;279(2):630-40
61. Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. *Liver Int* 2016;36(8):1108-15
62. Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys. *Hepatol Int* 2016;10(3):470-7
63. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. *J Viral Hepat* 2016;23(5):358-65
64. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. *Korean J Intern Med* 2016;31(2):242-52
65. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. *Liver Int* 2016 Aug;36(8):1196-205
66. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. *Hepatol Int* 2016;10(6):947-955
67. Synergistic effects of CD44 and TGF- β 1 through AKT/GSK-3 β / β -catenin signaling during epithelial-mesenchymal transition in liver cancer cells. *Biochem Biophys Res Commun* 2016;477(4):568-574
68. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. *Oncotarget* 2016;7(17):23482-97
69. Risk factors of biliary intervention by imaging after living donor liver transplantation. *World J Gastroenterol* 2016;22(7):2342-8
70. *Helicobacter pylori* infection is not associated with nonalcoholic fatty liver disease. *World J Gastroenterol* 2016;22(8):2592-600
71. Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A. *Gut Liver* 2016;10(2):288-94